Evaluation of a syndromic panel polymerase chain reaction (spPCR) assay for the diagnosis of device associated bone and joint infections (BJI)
Standard
Evaluation of a syndromic panel polymerase chain reaction (spPCR) assay for the diagnosis of device associated bone and joint infections (BJI). / Berneking, Laura; Haas, Michaela; Frielinghaus, Lisa; Berinson, Benjamin; Lütgehetmann, Marc; Christner, Martin; Aepfelbacher, Martin; Gerlach, Ulf; Seide, Klaus; Both, Anna; Rohde, Holger.
in: INT J INFECT DIS, Jahrgang 116, 03.2022, S. 283-288.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Evaluation of a syndromic panel polymerase chain reaction (spPCR) assay for the diagnosis of device associated bone and joint infections (BJI)
AU - Berneking, Laura
AU - Haas, Michaela
AU - Frielinghaus, Lisa
AU - Berinson, Benjamin
AU - Lütgehetmann, Marc
AU - Christner, Martin
AU - Aepfelbacher, Martin
AU - Gerlach, Ulf
AU - Seide, Klaus
AU - Both, Anna
AU - Rohde, Holger
N1 - Copyright © 2022. Published by Elsevier Ltd.
PY - 2022/3
Y1 - 2022/3
N2 - OBJECTIVE: Pathogen detection is crucial for diagnosis and targeted therapy in implant-associated bone and joint infections (BJI). Culture-based microbiology regularly fails to identify causative pathogens. This study evaluated the diagnostic accuracy and clinical usefulness of a syndromic panel polymerase chain reaction (spPCR) assay targeting common BJI pathogens in tissue specimens from patients with implant-associated BJI.METHODS: Results obtained by spPCR assay and a 16S rDNA PCR were compared with results obtained from a standard of care (SOC) culture-based diagnostics, serving as a gold standard. In total, 126 specimens obtained from 73 patients were analyzed.RESULTS: The spPCR assay correctly identified 33/40 culture-positive samples (82.5 %) and was positive in 9/86 (10.5 %) culture-negative samples, resulting in an overall sensitivity of 84.6 % (95% confidence interval [CI] 68.79-93.59%) and specificity of 89.35% (95% CI 80.6-94.81%). The spPCR was more sensitive compared with the 16S rDNA PCR (37.5%). The spPCR identified pathogens in 7/51 (13.7%) SOC-negative patients. Re-evaluation of spPCR results in clinical context suggested their clinical significance.CONCLUSION: An spPCR assay targeting common pathogens causing implant-associated BJI may help to identify causative agents in culture-negative cases. As false-negative results are possible, spPCR assays appear as an add-on approach for pathogen detection in implant-associated BJI.
AB - OBJECTIVE: Pathogen detection is crucial for diagnosis and targeted therapy in implant-associated bone and joint infections (BJI). Culture-based microbiology regularly fails to identify causative pathogens. This study evaluated the diagnostic accuracy and clinical usefulness of a syndromic panel polymerase chain reaction (spPCR) assay targeting common BJI pathogens in tissue specimens from patients with implant-associated BJI.METHODS: Results obtained by spPCR assay and a 16S rDNA PCR were compared with results obtained from a standard of care (SOC) culture-based diagnostics, serving as a gold standard. In total, 126 specimens obtained from 73 patients were analyzed.RESULTS: The spPCR assay correctly identified 33/40 culture-positive samples (82.5 %) and was positive in 9/86 (10.5 %) culture-negative samples, resulting in an overall sensitivity of 84.6 % (95% confidence interval [CI] 68.79-93.59%) and specificity of 89.35% (95% CI 80.6-94.81%). The spPCR was more sensitive compared with the 16S rDNA PCR (37.5%). The spPCR identified pathogens in 7/51 (13.7%) SOC-negative patients. Re-evaluation of spPCR results in clinical context suggested their clinical significance.CONCLUSION: An spPCR assay targeting common pathogens causing implant-associated BJI may help to identify causative agents in culture-negative cases. As false-negative results are possible, spPCR assays appear as an add-on approach for pathogen detection in implant-associated BJI.
U2 - 10.1016/j.ijid.2022.01.013
DO - 10.1016/j.ijid.2022.01.013
M3 - SCORING: Journal article
C2 - 35031396
VL - 116
SP - 283
EP - 288
JO - INT J INFECT DIS
JF - INT J INFECT DIS
SN - 1201-9712
ER -